- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.06. | FDA approves CSL's Andembry to prevent hereditary angioedema attacks | ||
| 19.06. | Galderma shares positive long-term data for Nemluvio in prurigo nodularis | ||
| 19.06. | Maximising the potential of AI in pharma | ||
| 19.06. | Local muscle, global impact | ||
| 18.06. | Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition | ||
| 18.06. | FDA unveils new voucher programme to accelerate drug review process | ||
| 18.06. | AstraZeneca's Ultomiris shows promise in rare post-transplant complication | ||
| 18.06. | Achieving gender parity - designing clinical trials with women in mind | ||
| 17.06. | Roche to advance Parkinson's disease candidate into phase 3 development | ||
| 17.06. | Novartis shares positive late-stage results for Fabhalta in rare blood disorder PNH | ||
| 17.06. | FDA approves new presentation of Celltrion's SteQeyma for paediatric psoriasis | ||
| 17.06. | Bridging the gap: from awareness to action in health equity | ||
| 16.06. | Merck's perioperative Keytruda regimen approved by FDA for head and neck cancer | ||
| 16.06. | AstraZeneca and CSPC Pharmaceuticals enter AI-driven partnership worth $5.3bn | ||
| 16.06. | Moderna's RSV vaccine mRESVIA granted FDA approval to protect younger adults | ||
| 16.06. | Duchenne muscular dystrophy - diagnosis, clinical development and global research | ||
| 13.06. | BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition | ||
| 13.06. | GSK's Blenrep combination recommended by NICE to treat multiple myeloma | ||
| 13.06. | FDA approves tablet formulation of BeOne's targeted cancer drug Brukinsa | ||
| 13.06. | Patient partnerships for life | ||
| 12.06. | FDA approves Nuvation Bio's TKI inhibitor Ibtrozi to treat rare form of lung cancer | ||
| 12.06. | Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones | ||
| 12.06. | Better together - accelerating innovation and access to rare disease treatments | ||
| 11.06. | UCB's Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials | ||
| 11.06. | NewAmsterdam's CETP inhibitor obicetrapib shows promise in Alzheimer's sub-study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .